Steven Cohen Ascendis Pharma A/S Transaction History
Point72 Asset Management, L.P.
- $40.1 Billion
- Q1 2025
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 569,146 shares of ASND stock, worth $104 Million. This represents 0.22% of its overall portfolio holdings.
Number of Shares
569,146
Previous 569,146
-0.0%
Holding current value
$104 Million
Previous $88.7 Million
-0.0%
% of portfolio
0.22%
Previous 0.22%
Shares
14 transactions
Others Institutions Holding ASND
# of Institutions
276Shares Held
61.7MCall Options Held
151KPut Options Held
226K-
Ra Capital Management, L.P. Boston, MA10.3MShares$1.88 Billion33.28% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.48MShares$1 Billion4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.22MShares$953 Million13.16% of portfolio
-
Janus Henderson Group PLC London, X04.49MShares$819 Million0.4% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$777 Million1.14% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $10.2B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...